Search Results

The intended use of the GammaMed Plus transportable high-dose-rate remotely controlled afterloading brachytherapy device is for the treatment of cancer by intracavitary, interstitial, intralumenal and intraoperative irradiation.

The GammaMed Plus is a transportable high-dose-rate remotely controlled afterloading brachytherapy device. The unit is designed to provide a predetermined dose of radiation to tissues and organs by means of manipulating a radioactive source from a shielded position within the device into an applicator, which has been previously placed within or on a patient. The GammaMed plus system is based on a further development of the existing GammaMed 12it system. The GammaMed plus system consists of the following components: Treatment device including computer and control software, Applicators and accessories, Treatment planning system.

This document is a 510(k) summary for the GammaMed Plus High Dose Rate Remote Afterloading System. It outlines the device's characteristics, intended use, and its substantial equivalence to a legally marketed predicate device (GammaMed 12it).

However, the provided text does not include any information about acceptance criteria, device performance, or a study conducted to prove the device meets said criteria. The document focuses on regulatory approval based on substantial equivalence, primarily by describing engineering changes and stating that these changes do not adversely affect safety or effectiveness.

Therefore, I cannot fulfill your request for information regarding acceptance criteria, reported device performance, sample sizes, ground truth establishment, or multi-reader multi-case studies, as this information is not present in the provided text.

Ask a specific question about this device